• 5 min read
• Published on 21 October 2025
Listen to article
5:40Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Let’s be honest, for years the global supply chain has felt like a rather precarious game of Jenga. We pull out bits from here, there, and everywhere, hoping the whole tower doesn't come crashing down. Then, a global pandemic came along and gave the table a good, hard shove. Suddenly, the realisation that your nation’s essential medicines are made thousands of miles away didn't seem quite so clever. It seems Merck agrees, and they’re putting a cool £3 billion where their mouth is.
Merck’s plan to build a sprawling new manufacturing plant in Virginia isn't just a line item in an annual report. To me, it’s a flag planted firmly in the ground. It’s a declaration that the old way of doing things, chasing the lowest labour costs across the globe, has run its course. The hidden costs of that model, from shipping delays to geopolitical spats, have finally become too high a price to pay.
This isn't about charity or flag-waving patriotism. It’s a cold, pragmatic calculation. When your supply chain snaps, you don't just lose money, you lose trust. You risk empty pharmacy shelves and public outcry. This investment is an insurance policy, a bet on stability and control in an increasingly unstable world. It’s a recognition that for something as critical as medicine, ‘just in time’ can quickly become ‘not at all’.
Of course, Merck isn’t acting in a vacuum. When a giant like that makes such a move, others are bound to take notice. You can be sure that boardrooms at Pfizer and Eli Lilly are having similar conversations. They have the scale and the resources to follow suit, turning this single investment into a genuine industry-wide shift. This isn't just about one company, it's about rebuilding an entire industrial ecosystem.
This trend creates a fascinating ripple effect for investors. It’s not just the pharmaceutical titans themselves that could stand to benefit. Think about it. Who builds these high-tech facilities? Who supplies the advanced robotics and specialised equipment? Who handles the logistics of a revitalised domestic supply chain? The opportunities spread far and wide. To get a real sense of the scale here, it's worth looking at the bigger picture of Pharma Onshoring: What's Next for US Drug Supply.
For decades, the argument against domestic manufacturing was simple, it was too expensive. That logic is starting to look rather dated. Modern pharmaceutical production is less about armies of workers and more about sophisticated automation. When robots are doing the heavy lifting, the wage difference between Virginia and Shanghai becomes far less important.
What’s more, governments are now sweetening the deal. They see healthcare security as a matter of national security, on par with energy or defence. This means regulatory tailwinds and potential incentives for companies willing to bring production home. Suddenly, the economic equation looks very different. The long-term security and speed to market offered by a domestic facility might just outweigh the short-term cost savings of offshoring. It’s a long game, but it’s one that big pharma now seems determined to play.
View the full Basket:Pharma Onshoring: What's Next for US Drug Supply
View the full Basket:Pharma Onshoring: What's Next for US Drug Supply
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article